Quanterix (NASDAQ:QTRX – Get Free Report) is one of 109 public companies in the “Life Sciences Tools & Services” industry, but how does it compare to its rivals? We will compare Quanterix to similar companies based on the strength of its valuation, dividends, earnings, analyst recommendations, institutional ownership, profitability and risk.
Insider & Institutional Ownership
86.5% of Quanterix shares are owned by institutional investors. Comparatively, 53.5% of shares of all “Life Sciences Tools & Services” companies are owned by institutional investors. 1.5% of Quanterix shares are owned by company insiders. Comparatively, 15.0% of shares of all “Life Sciences Tools & Services” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Volatility and Risk
Quanterix has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500. Comparatively, Quanterix’s rivals have a beta of 0.94, suggesting that their average share price is 6% less volatile than the S&P 500.
Profitability
This table compares Quanterix and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Quanterix | -75.05% | -30.49% | -22.44% |
| Quanterix Competitors | -487.52% | 78.70% | -13.00% |
Valuation and Earnings
This table compares Quanterix and its rivals top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Quanterix | $138.90 million | -$107.15 million | -0.83 |
| Quanterix Competitors | $2.27 billion | $55.87 billion | -7.35 |
Quanterix’s rivals have higher revenue and earnings than Quanterix. Quanterix is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Analyst Ratings
This is a summary of current ratings and recommmendations for Quanterix and its rivals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Quanterix | 1 | 2 | 0 | 0 | 1.67 |
| Quanterix Competitors | 960 | 3205 | 5534 | 179 | 2.50 |
Quanterix presently has a consensus target price of $3.50, suggesting a potential upside of 78.57%. As a group, “Life Sciences Tools & Services” companies have a potential upside of 5.31%. Given Quanterix’s higher probable upside, research analysts plainly believe Quanterix is more favorable than its rivals.
Summary
Quanterix rivals beat Quanterix on 8 of the 12 factors compared.
About Quanterix
Quanterix Corporation develops technologies for measuring biomarkers in biological samples. Its Simoa (Single Molecule Array) platform is designed to detect proteins and other biomarkers at very low concentrations, supporting research in areas such as neurology, oncology, immunology and cardiovascular disease. The company provides laboratory instruments, assay kits, consumables and related services. Its products are used by pharmaceutical and biotechnology companies, academic institutions and laboratories to study disease biology and evaluate potential biomarkers in samples such as blood and cerebrospinal fluid.
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.
